PMC:7079862 / 42721-43628 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1410","span":{"begin":589,"end":597},"obj":"Species"},{"id":"1411","span":{"begin":111,"end":120},"obj":"Species"},{"id":"1412","span":{"begin":183,"end":192},"obj":"Species"},{"id":"1413","span":{"begin":229,"end":238},"obj":"Species"},{"id":"1414","span":{"begin":314,"end":323},"obj":"Species"},{"id":"1415","span":{"begin":685,"end":694},"obj":"Species"},{"id":"1419","span":{"begin":337,"end":353},"obj":"Disease"}],"attributes":[{"id":"A1410","pred":"tao:has_database_id","subj":"1410","obj":"Tax:1335626"},{"id":"A1411","pred":"tao:has_database_id","subj":"1411","obj":"Tax:11520"},{"id":"A1412","pred":"tao:has_database_id","subj":"1412","obj":"Tax:11520"},{"id":"A1413","pred":"tao:has_database_id","subj":"1413","obj":"Tax:11520"},{"id":"A1414","pred":"tao:has_database_id","subj":"1414","obj":"Tax:11520"},{"id":"A1415","pred":"tao:has_database_id","subj":"1415","obj":"Tax:11520"},{"id":"A1419","pred":"tao:has_database_id","subj":"1419","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T284","span":{"begin":111,"end":120},"obj":"Disease"},{"id":"T285","span":{"begin":183,"end":192},"obj":"Disease"},{"id":"T286","span":{"begin":229,"end":238},"obj":"Disease"},{"id":"T287","span":{"begin":246,"end":248},"obj":"Disease"},{"id":"T288","span":{"begin":314,"end":323},"obj":"Disease"},{"id":"T289","span":{"begin":337,"end":353},"obj":"Disease"},{"id":"T290","span":{"begin":512,"end":514},"obj":"Disease"},{"id":"T291","span":{"begin":530,"end":532},"obj":"Disease"},{"id":"T292","span":{"begin":685,"end":694},"obj":"Disease"}],"attributes":[{"id":"A284","pred":"mondo_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A285","pred":"mondo_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A286","pred":"mondo_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A287","pred":"mondo_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/MONDO_0017319"},{"id":"A288","pred":"mondo_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A289","pred":"mondo_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A290","pred":"mondo_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/MONDO_0017319"},{"id":"A291","pred":"mondo_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/MONDO_0017319"},{"id":"A292","pred":"mondo_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T295","span":{"begin":286,"end":298},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T296","span":{"begin":533,"end":536},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T297","span":{"begin":542,"end":543},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T298","span":{"begin":578,"end":584},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T265","span":{"begin":567,"end":577},"obj":"Chemical"}],"attributes":[{"id":"A265","pred":"chebi_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T23","span":{"begin":337,"end":353},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}

{"project":"LitCovid-sentences","denotations":[{"id":"T300","span":{"begin":0,"end":907},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Dr. Hayden’s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support."}